Detalles de la búsqueda
1.
Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Oncologist
; 26(2): e290-e297, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32918790
2.
Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
Cancer Control
; 27(1): 1073274820902271, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107929
3.
First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.
Head Neck
; 45(9): 2246-2258, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37435624
4.
Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma.
Front Immunol
; 14: 1258344, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37744335
5.
Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
Oral Oncol
; 129: 105871, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35483156
6.
Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Front Oncol
; 12: 904372, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36176384
7.
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.
Front Oncol
; 10: 1649, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33014826
8.
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Adv Ther
; 37(5): 2116-2126, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32193809
9.
Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
J Med Econ
; 22(6): 584-592, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30808230
10.
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
Lung Cancer
; 138: 88-94, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31655368
Resultados
1 -
10
de 10
1
Próxima >
>>